A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance

Platinum(IV) complexes have the potential to overcome several limitations and reduce adverse effects of platinum-based cancer therapy. Resistance to clinically approved platinum(II) drugs is, at least in part, associated with elevated levels of glutathione. Here, the authors report on an oxaliplatin...

Full description

Bibliographic Details
Main Authors: Philipp Fronik, Michael Gutmann, Petra Vician, Mirjana Stojanovic, Alexander Kastner, Petra Heffeter, Christine Pirker, Bernhard K. Keppler, Walter Berger, Christian R. Kowol
Format: Article
Language:English
Published: Nature Portfolio 2022-04-01
Series:Communications Chemistry
Online Access:https://doi.org/10.1038/s42004-022-00661-z

Similar Items

Similar Items